参考文献/References:
[1] Yanase T,Oki Y,Katabami T,et al.New diagnostic criteria of adrenal subclinical Cushing's syndrome: opinion from the Japan Endocrine Society[J]. Endocr J,2018,65(4):383-393.DOI:10.1507/endocrj.EJ17-0456.
[2] 中华医学会内分泌学分会.库欣综合征专家共识[J].中华内分泌代谢杂志,2012, 28(2):96-102.DOI:10.3760/cma.j.issn.1000-6699.2012.02.002.
[3] Fassnacht M,Arlt W,Bancos I,et al.Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors[J].Eur J Endocrinol,2016,175(2):G1-G34.DOI:10.1530/EJE-16-0467.
[4] Kageyama K,Oki Y,Nigawara T,et al.Pathophysiology and treatment of subclinical Cushing's disease and pituitary silent corticotroph adenomas [J].Endocr J,2014,61(10):941-948.
[5] Reincke M,Allolio B,Saeger W,et al.A pituitary adenoma secreting high molecular weight adrenocorticotropin without evidence of Cushing's disease[J].J Clin Endocrinol Metab,1987,65(6):1296-1300.DOI:10.1210/jcem-65-6-1296.
[6] Minami I,Tateno T,Yoshimoto T,et al.Subclinical Cushing's disease with amelioration of metabolic comorbidities after removal of pituitary tumor[J].Intern Med,2006,45(21):1231-1235.
[7] Ohmori N,Nomura K,Ohmori K,et al.Preclinical Cushing's disease characterized by massive adrenal hyperplasia and hormonal changes after three years of metyrapone therapy[J].Endocr J,2007,54(3):391-397.
[8] Tsuchiya K,Ohta K,Yoshimoto T,et al.A case of acromegaly associated with subclinical Cushing's disease[J].Endocr J,2006,53(5):679-685.
[9] Tourtelot JB,Vesely DL.Pituitary tumor with gigantism, acromegaly and preclinical Cushing's disease diagnosed from the 10th row[J].Am J Med Sci,2013,346(2):169-171.DOI:10.1097/MAJ.0b013e3182831919.
[10] Oki K,Yamane K,Oda Y,et al.Combined acromegaly and subclinical Cushing's disease related to high-molecular-weight adrenocorticotropic hormone[J].J Neurosurg,2009,110(2):369-373.DOI:10.3171/2008.8.JNS08154.
[11] Murakami H,Nigawara T,Sakihara S,et al.The frequency of type 2 diabetic patients who meet the endocrinological screening criteria of subclinical Cushing's disease[J].Endocr J,2010,57(3):267-272.
[12] Andrioli M,Pecori Giraldi F,Losa M,et al.Cushing's disease due to double pituitary ACTH-secreting adenomas: the first case report[J].Endocr J,2010,57(9):833-837.
[13] Kobayashi Y,Takei M,Ohkubo Y,et al.A somatotropin-producing pituitary adenoma with an isolated adrenocorticotropin-producing pituitary adenoma in a female patient with acromegaly, subclinical Cushing's disease and a left adrenal tumor[J].Endocr J,2014,61(6):589-595.
[14] Tamada D,Kitamura T,Otsuki M,et al.Clinical significance of screening for subclinical Cushing's disease in patients with pituitary tumors[J].Endocr J,2016,63(1):47-52.DOI:10.1507/endocrj.EJ15-0446.
[15] Takiguchi T,Koide H,Nagano H,et al.Multihormonal pituitary adenoma concomitant with Pit-1 and Tpit lineage cells causing acromegaly associated with subclinical Cushing's disease: a case report[J].BMC Endocr Disord,2017,17(1):54. DOI:10.1186/s12902-017-0203-5.
[16] Trifanescu R,Carsote M,Caragheorgheopol A,et al.Screening for secondary endocrine hypertension in young patients[J].Maedica(Buchar),2013,8(2):108-115.
[17] Budyal S,Jadhav SS,Kasaliwal R,et al.Is it worthwhile to screen patients with type 2 diabetes mellitus for subclinical Cushing's syndrome?[J].Endocr Connect,2015,4(4):242-248.DOI:10.1530/EC-15-0078.
[18] Terzolo M,Reimondo G,Chiodini I,et al.Screening of Cushing's syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy[J].J Clin Endocrinol Metab,2012,97(10):3467-3475.DOI:10.1210/jc.2012-1323.
[19] Zeiger MA,Thompson GB,Duh QY,et al.The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas[J].Endocr Pract,2009,15(Suppl 1):1-20.DOI:10.4158/EP.15.5.450.
[20] Oki Y,Hashimoto K,Hirata Y,et al.Development and validation of a 0.5 mg dexamethasone suppression test as an initial screening test for the diagnosis of ACTH-dependent Cushing's syndrome[J].Endocr J,2009,56(7):897-904.
[21] Nagai T,Imamura M,Misumi S,et al.Subclinical Cushing's disease accompanied by malignant hypertension and diabetes mellitus[J].Intern Med,2002,41(7):566-570.
[22] Nieman LK,Biller BM,Findling JW,et al.Treatment of Cushing's Syndrome: an Endocrine Society Clinical Practice Guideline[J].J Clin Endocrinol Metab,2015,100(8):2807-2831.DOI:10.1210/jc.2015-1818.
[23] Ebisawa T,Tojo K,Tajima N,et al.Immunohistochemical analysis of 11-beta-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical Cushing's disease due to pituitary macroadenoma[J].Endocr Pathol,2008,19(4):252-260. DOI:10.1007/s12022-008-9052-0.
[24] Tabuchi Y,Kitamura T,Fukuhara A,et al. Nur77 gene expression levels were involved in different ACTH-secretion autonomy between Cushing's disease and subclinical Cushing's disease[J].Endocr J,2016,63(6):545-554.DOI:10.1507/endocrj.EJ15-0695.